Study participants were allowed to continue all existing medications throughout the study protocol. Participants who had recently changed their medications were not allowed to begin the study protocol until their other treatments had been taken at steady dosages for at least 2 months. Participants were instructed to keep other medications at stable dosages throughout the trial and to report any actual or potential changes in their treatment regimen to the research personnel. The majority of participants were taking at least 1 other medication.
Crohns (published 2011) 34 people completed the trial out of 40:-
Patients taking stable doses of medications for Crohn’s disease were allowed to enroll with the following stipulations: 4 weeks of stable medications prior to screening for aminosalicylates and steroids (prednisone at 10 mg or less daily and budesonide at 3 mg/day), and 12 weeks for thiopurines (azathioprine or 6-mercaptopurine). These medications were maintained at the same dose throughout the duration of the study.
MS (published 2010) 60 people completed the trial out of 80:-
Side effect Placebo LDN
Vivid dreams 7 10 Fatigue 2 1 Flu like symptoms 1 0 Insomnia 1 0 Loss of appetite 0 1 Sinus infection 0 1 Euphoria 0 0
Indeed, there is a misconception among some MS patients that LDN is incompatible with IFN usage, and the present study did not find evidence of such antagonism.
